- Home
- GHRS vs SPRY Comparison
GHRS vs SPRY Comparison
Compare GHRS & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GHRS | SPRY |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 947.2M | 823.2M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GHRS | SPRY |
|---|---|---|
| Price | $21.45 | $8.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $41.38 | $40.00 |
| AVG Volume (30 Days) | 252.6K | ★ 1.6M |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | N/A | $87.40 |
| Revenue Next Year | N/A | $81.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.52 | $6.66 |
| 52 Week High | $24.66 | $18.63 |
Technical Indicators
Market Signals| Indicator | GHRS | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 62.50 | 53.70 |
| Support Level | $12.41 | $8.61 |
| Resistance Level | $24.66 | $9.46 |
| Average True Range (ATR) | 1.48 | 0.49 |
| MACD | 0.08 | 0.11 |
| Stochastic Oscillator | 68.22 | 53.39 |
Price Performance
Historical ComparisonAbout GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.